Please see https://drive.google.com/drive/folders/1WD618wrywYjEaXzfLTcuK-VCcnb6b-gV for full code and algorithm definitions.  Eligible cohort entry dates:  The degarelix indication for treatment of prostate cancer was approved by the FDA on Dec 24, 2008. Leuprolide was initially approved for the same indication prior to Dec 24, 2008.  IBM MarketScan: Dec 24, 2008 - December 31, 2018 (end of available data) Optum CDM: Dec 24, 2008 - June 30, 2020 (end of available data) CMS Diabetes: Dec 24, 2008 - Dec 31, 2017 (end of available data)  Inclusion Criteria:  Histologically confirmed adenocarcinoma of the prostate Pre-existing ASCVD (confirmed diagnosis, documented) according to a least 1 of the following criteria: Previous MI >= 30 days before randomization Previous revascularization procedure >= 30 days before randomization Coronary artery: stent placement/balloon angioplasty or coronary artery bypass graft surgery Carotid artery: stent placement/balloon angioplasty or endarterectomy surgery Iliac, femoral, popliteal arteries: stent placement/balloon angioplasty or vascular bypass surgery  Exclusion Criteria:  Treatment naivety (ADT) Previous or current hormonal management of prostate cancer including surgical castration, any hormonal manipulation, or any previous neoadjuvant/adjuvant hormonal therapy, unless treatment was terminated more than 12 months prior to enrollment Uncontrolled Type 1 or Type 2 diabetes mellitus Uncontrolled hypertension A history of congenital long QT syndrome or risk factors for Torsade de pointes ventricular arrhythmias MI; stroke; or coronary, carotid, or peripheral artery revascularization